🇺🇸 dalfampridine ER in United States

408 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 74 reports (18.14%)
  2. Product Substitution Issue — 71 reports (17.4%)
  3. Seizure — 48 reports (11.76%)
  4. Fall — 47 reports (11.52%)
  5. Gait Disturbance — 37 reports (9.07%)
  6. Therapy Cessation — 33 reports (8.09%)
  7. Urinary Tract Infection — 33 reports (8.09%)
  8. Condition Aggravated — 22 reports (5.39%)
  9. Therapy Non-Responder — 22 reports (5.39%)
  10. Death — 21 reports (5.15%)

Source database →

dalfampridine ER in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is dalfampridine ER approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for dalfampridine ER in United States?

Brown, Theodore R., M.D., MPH is the originator. The local marketing authorisation holder may differ — check the official source linked above.